In our study, the frequency of alternative splicing was significantly lower in patients with SIRS and severe sepsis/septic shock compared to the control cohort (Fig 2A), which vice versa could mean more enzymatically active ASM. This evidence concerns the gene SMPD1 and Sepsis.